BH7-HM177-100μg / 询价
BH7-HM177-500μg / 询价
BH7-HM177-500μgx2 / 询价
Human B7-H7/HHLA2 Protein
Recombinant Human B7-H7/HHLA2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ile23-Asn344 [Accession | Q9UM44-1].
The protein has a predicted MW of 38.1 kDa. Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human B7-H7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human B7-H7 is greater than 95% as determined by SEC-HPLC.
Immobilized Human B7-H7, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Human CD28H, hFc Tag with the EC50 of 63.4 ng/ml determined by ELISA (QC Test).
B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins.Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade.
B7H7; B7-H7; HHLA2; B7 Homolog 7
(1) Leung J , Suh W K. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy[J]. Immune Network, 2014, 14(6).
